Join Diane Ramsden, PhD, and Lindsey Whaley, MS, for an inside look at TruVivo™, a novel all-human in vitro hepatocyte system developed by LifeNet Health LifeSciences.

Current in vitro hepatic models, such as sandwich cultures, lose key hepatocellular function and enzymatic activity over time. More advanced co-culture platforms have been introduced but are often complex or contain non-human cells that can alter results due to innate background contribution to metabolism. These limitations make it challenging to characterize human mechanisms for the metabolism of drug candidates, especially those that are slowly metabolized. To address these limitations, TruVivo was developed as the first and only 2D+ hepatic system to provide human-relevant, reliable results in an easy-to-use format.

In this webinar, Lindsey Whaley introduces key features of the TruVivo system that demonstrate its potential to be an ideal platform for drug discovery and development applications. Diane Ramsden then presented data from her evaluation of TruVivo as a potential tool for investigating mechanistic drug metabolism and pharmacokinetics, including drug-drug interaction potential, and translational risk assessment.

Key Topics Include:

  • The advantages of the system – which offers the simplicity of a 2D model, with the robust levels of data typical of 3D models.
  • An overview of how TruVivo mimics the microarchitecture and functionality of the human liver.
  • How hepatocytes are pre-qualified in the system to reduce variability for a broad range of pharmacological and toxicological applications.
  • Drug metabolizing enzyme activity and retention over the use period.
  • Translation of in vitro derived parameters to conduct DDI risk assessment.


Oncology DMPK

Diane Ramsden is a Director and ADME BA group leader within AstraZeneca Oncology. She has worked in the pharmaceutical industry for over 20 years and has a range of experience in project representation from early discovery stage to post marketing in multiple therapeutic and disease areas including Oncology, GI, NS, cardiometabolic, respiratory, immunology and rare diseases and across modalities including small molecule drugs, PROTACs, microbiome-based therapeutics, mAbs, ADCs and RNAi.

Product Manager
LifeNet Health

As LifeSciences product manager, Lindsey has a passion for driving innovation and delivering exceptional user experiences. Known for her collaborative approach and ability to translate marketing insights into actionable strategies, Lindsey is dedicated to delivering products that align with core customer needs. Lindsey holds a bachelor’s degree in biology and a master’s degree in biotechnology. During her academic journey, she completed two internships at LifeNet Health focused on various LifeSciences marketing projects where she quickly developed a passion for making high-quality, human research solutions accessible to scientific researchers. In her role as Product Manager for LifeNet Health LifeSciences, Lindsey collaborates with cross-functional teams to manage new product releases and an existing portfolio to a global market. She most enjoys using her scientific background to effectively communicate the benefits of LifeSciences’ innovation portfolio to the scientific community.

Production Partner

LifeNet Health LifeSciences

LifeNet Health LifeSciences leads the way in human in vitro biology for both non-diseased and diseased research needs. LifeNet Health LifeSciences combines innovative, technology-driven research and development programs to create human tissue and cell-based research products and services.

Additional Content From LifeNet Health LifeSciences

A Novel, All-Human Hepatic Triculture System

A Novel, All-Human Hepatic Triculture System

Join Edward LeCluyse and Paul Gallant as they offer insight into a novel, all-human hepatic triculture and how this unique system addresses the need for a convenient and human-relevant long-term hepatic culture.

Additional Content From

Related Content